2022
Myeloid-derived suppressor cells: a grey eminence in the AML tumor microenvironment?
Bewersdorf JP, Zeidan AM. Myeloid-derived suppressor cells: a grey eminence in the AML tumor microenvironment? Expert Review Of Anticancer Therapy 2022, 22: 239-241. PMID: 35034557, DOI: 10.1080/14737140.2022.2030227.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2020
Novel and combination therapies for polycythemia vera and essential thrombocythemia: the dawn of a new era
Bewersdorf JP, Zeidan AM. Novel and combination therapies for polycythemia vera and essential thrombocythemia: the dawn of a new era. Expert Review Of Hematology 2020, 13: 1189-1199. PMID: 33076714, PMCID: PMC7722191, DOI: 10.1080/17474086.2020.1839887.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsBone MarrowClinical Trials as TopicCombined Modality TherapyDNA MethylationDrugs, InvestigationalForecastingHistone CodeHumansHydroxyureaInflammationInterferon-alphaJanus Kinase 2Molecular Diagnostic TechniquesMolecular Targeted TherapyMutation, MissenseNitrilesPolycythemia VeraPyrazolesPyrimidinesSignal TransductionTherapies, InvestigationalThrombocythemia, EssentialThrombophiliaThrombosisTumor MicroenvironmentConceptsEssential thrombocythemiaPolycythemia veraNovel agentsPV patientsTreatment selectionHigh-risk essential thrombocythemiaAberrant immune regulationFirst-line treatmentDisease-modifying potentialRecent clinical trialsNegative myeloproliferative neoplasmsBone marrow microenvironmentImmune pathobiologyCombination therapyClinical trialsClinical studiesImmune regulationPV pathogenesisConference abstractsBCR-ABL1Individualized approachMolecular testingClonal proliferationMyeloproliferative neoplasmsPatients
2019
Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled
Bewersdorf JP, Stahl M, Zeidan AM. Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled. Expert Review Of Anticancer Therapy 2019, 19: 393-404. PMID: 30887841, PMCID: PMC6527485, DOI: 10.1080/14737140.2019.1589374.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAnimalsAntineoplastic Agents, ImmunologicalHumansImmunotherapyLeukemia, Myeloid, AcuteMyelodysplastic SyndromesTumor MicroenvironmentConceptsImmune checkpoint-based therapyImmune checkpoint inhibitorsAcute myeloid leukemiaMyelodysplastic syndromeNon-small cell lung cancerMultiple immune checkpoint inhibitorsTumor microenvironmentHematopoietic stem cell transplantAdvanced solid malignanciesStem cell transplantCell lung cancerInhibitory immune checkpointsImmunosuppressive tumor microenvironmentType of therapyMinimal residual diseaseInduction chemotherapyMonotherapy useRefractory settingCheckpoint inhibitorsImmune checkpointsTumor cell survivalCell transplantResidual diseaseSafety profileImmune system evasion